SCHEMBL8738356

SCHEMBL8738356

CNC(=O)c1ccc(OC)c(Nc2nc(-c3sc(N)nc3C)cs2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.70
KMT2A Q03164 14/20 0.70
MAPT P10636 12/20 0.70
ALDH1A1 P00352 9/20 0.70
GAA P10253 8/20 0.70
TDP1 Q9NUW8 3/20 0.70
HSD17B10 Q99714 2/20 0.70
PDE5A O76074 1/20 0.65
PDE1A P54750 1/20 0.65
PDE1B Q01064 1/20 0.65
PDE1C Q14123 1/20 0.65
CFTR P13569 4/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
KDM4E B2RXH2 6/20 0.58
SMN1; SMN2 Q16637 5/20 0.58
HPGD P15428 5/20 0.58
LMNA P02545 4/20 0.58
ALB P02768 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6114192 0.90 MEN1 (0.73) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL6114077 0.90 MEN1 (0.73) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8738343 0.90 MEN1 (0.73) MEN1KMT2AMAPTALDH1A1GAA
Bromide SCHEMBL6114277 0.89 MEN1 (0.71) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8737940 0.88 MMP9 (0.72) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8738033 0.87 MEN1 (0.63) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8739499 0.84 MEN1 (0.82) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8737946 0.84 MEN1 (0.82) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8738403 0.83 MEN1 (0.70) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL8737941 0.82 MEN1 (0.71) MEN1KMT2AMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MEN1 2298/4885KMT2A 2435/4885MAPT 3531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.